Quarterly Result2 Jan 2026, 07:51 pm
Corona Remedies Ltd Reports 15.1% Revenue Growth in Q2FY26, 35.1% PAT Growth in H1FY26
AI Summary
Corona Remedies Limited, a leading branded pharmaceutical formulation company, has announced its financial results for Q2 and H1 FY26. The company reported a revenue growth of 15.1% and 17.0% for Q2 and H1FY26 respectively, and a PAT growth of 21.8% and 35.1% for the same periods. The company's ROE and ROCE stood at 31.1% and 49.7% respectively in H1 FY26. The strong performance is attributed to the company's focus on core therapeutic segments and strategic execution.
Key Highlights
- Revenue grew by 15.1% in Q2FY26 and 17.0% in H1FY26
- PAT grew by 21.8% in Q2FY26 and 35.1% in H1FY26
- ROE and ROCE stood at 31.1% and 49.7% respectively in H1 FY26
- Strong performance due to focus on core therapeutic segments and strategic execution
- Company thanks bankers and stakeholders for their support